Boron neutron capture therapy. Clinical brain tumor studies.
Since 1968, we have treated 149 patients and performed boron-neutron capture therapy (BNCT) on 164 occasions using 5 reactors in Japan. There were 64 patients with glioblastoma, 39 patients with anaplastic astrocytoma and 17 patients with low grade astrocytoma (grade 1 or 2). There were 30 patients with other types of tumor. The overall response rate in the glioma patients was 64%. Seven patients (12%) of glioblastoma, 22 patients (56%) of anaplastic astrocytoma and 8 patients (62%) of low grade astrocytoma lived more than 2 years. Median survival time of glioblastoma was 640 days. Median survival times of patients with anaplastic astrocytoma was 1811 days, and 1669 days in low grade astrocytoma. Six patients (5 glioblastoma and one anaplastic astrocytoma) died within 90 days after BNCT. Six patients (two glioblastoma and four anaplastic astrocytomas) lived more than 10 years. Histological grading, age of the patients, neutron fluence at the target point and target depth or size of the tumor were proved to be important factors. BNCT is an effective treatment for malignant brain tumors. We are now able to radiate the tumor more correctly with a high enough dose of neutron beam, even if we use thermal neutron beam.
Nakagawa
Y
Y
Department of Neurosurgery, National Kagawa Children's Hospital, Japan.
Hatanaka
H
H
D000328:Adult; D001254:Astrocytoma / Q000401:mortality / Q000532:radiotherapy*; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000145:classification / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D018572:Disease-Free Survival; D005909:Glioblastoma / Q000401:mortality / Q000532:radiotherapy*; D005910:Glioma / Q000145:classification / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors